| Name | Title | Contact Details |
|---|
Healthcare industry veterans Joe Caruncho – whose success at the helm of Preferred Care Partners led to annual sales in excess of $750 million – and Orlando Lopez-Fernandez, Jr., MD, founded Genuine Health Group to usher in a new era of healthcare delivery focused on value instead of volume. Today, Genuine Health is building a model for managing care delivery that embodies traditional values, promises reliability, and embraces flexibility and technology. Through its accountable care organization, PremierMD ACO, the company aims to improve healthcare outcomes, achieve cost savings for the care of patients who receive traditional, fee-for-service Medicare benefits, and serve as a single point of contact to move doctors` Medicare members into value-based care. And, through its management service organization (MSO), the company aims to deliver financial upside for its participating physicians whose patients are enrolled in Medicare Advantage plans. For both traditional Medicare beneficiaries and those who choose managed care plans, Genuine Health and its providers are demonstrating the powerful effects of value-based care.
NorthNode Group Counseling is Delaware`s rising mental health provider of choice for those who seek to improve their lives and learn to thrive through positive psychological talk therapy. Since 2016, NorthNode has served the various behavioral needs of children, young adults, adults, and senior citizens through our specially designed mental wellness programs.
Roberts Home Medical, Inc. is a Harrisonburg, VA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Scherago International is a Jersey City, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
StemCells, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery primarily in the United States. Its lead therapeutic product candidate, HuCNS-SC cells (purified human neural stem cells), is in development as a potential treatment for a range of central nervous system disorders. The company has conducted a Phase I clinical trial in Pelizaeus-Merzbacher disease, a fatal myelination disorder in children. It is also conducting a Phase I/II clinical trial in chronic spinal cord injury; and has initiated a Phase I/II clinical trial in dry age-related macular degeneration, as well as is pursuing preclinical studies in Alzheimer’s disease. In addition, the company markets a rage of proprietary cell culture products, research grade human cells, and antibody reagents under the SC Proven brand. The proprietary cell culture products include iSTEM, GS1-R, GS2-M, RHB-A, RHB-Basal, NDiff227, NDiff N2, and NDiff N27 supplements, as well as HEScGRO and ESGRO Complete; and antibody reagents comprise STEM24, STEM101, STEM121, and STEM123, which can be used for cell detection, isolation, and characterization. Further, StemCells is involved in developing and commercializing applications of its technologies to enable stem cell-based research. The company sells its tools and technologies products to researchers at academic institutions, pharmaceutical and biotechnology companies, and government laboratories. StemCells, Inc. was founded in 1988 and is headquartered in Newark, California.